A second prostate-specific membrane antigen (PSMA) PET scan changed treatment plans for nearly half of patients whose first scan was negative, according to new research published in the July issue of ...
It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...
Five-year results from the NRG-GU003 Phase III trial show that a 25-fraction, five-week postoperative radiation schedule ...
Timing and uptake of germline testing in patients with somatic BRCA1/2 pathogenic or likely pathogenic variants in solid tumors: A real-world study from community oncology practices. Identifying ...
Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...
Stockhead on MSN
ASX healthcare stocks advance new approaches to prostate cancer
ASX-listed healthcare companies are advancing new approaches to prostate cancer, spanning imaging, targeted therapies and ...
CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results